Abstract:
The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.
Abstract:
Described herein are neutral prodrugs of phosphorus-containing inhibitors of farnesyl transferase that include one or more phosphate fragments or analogs of phosphate fragments. Analogs of phosphate fragments include various linkers other than oxygen connecting the phosphate fragment to the remaining portion of the drug, such as but not limited to linkers forming phosphoramidates, phosphonates, difluorophosphonates, phosphordiamidates, and the like.
Abstract:
Described herein are neutral prodrugs of phosphorus-containing inhibitors of farnesyl transferase that include one or more phosphate fragments or analogs of phosphate fragments. Analogs of phosphate fragments include various linkers other than oxygen connecting the phosphate fragment to the remaining portion of the drug, such as but not limited to linkers forming phosphoramidates, phosphonates, difluorophosphonates, phosphordiamidates, and the like.
Abstract:
Described herein are neutral prodrugs of phosphorus-containing inhibitors of farnesyl transferase that include one or more phosphate fragments or analogs of phosphate fragments. Analogs of phosphate fragments include various linkers other than oxygen connecting the phosphate fragment to the remaining portion of the drug, such as but not limited to linkers forming phosphoramidates, phosphonates, difluorophosphonates, phosphordiamidates, and the like.
Abstract:
Phosphate-substituted therapeutic compounds and analogs thereof that may serve as prodrugs are described. The prodrugs may include phosphorus-containing compounds, drug-phosphate conjugates, and analogs of drug-phosphate conjugates. Also described are analogs of drugs, including phosphorylated drugs, where the linker connecting the phosphate fragment to the drug fragment is other than oxygen, such as but not limited to linkers forming phosphoramidates, phosphonates, difluorophosphonates, oxophosphonates, and the like.
Abstract:
The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.
Abstract:
Phosphate-substituted therapeutic compounds and analogs thereof that may serve as prodrugs are described. The prodrugs may include phosphorus-containing compounds, drug-phosphate conjugates, and analogs of drug-phosphate conjugates. Also described are analogs of drugs, including phosphorylated drugs, where the linker connecting the phosphate fragment to the drug fragment is other than oxygen, such as but not limited to linkers forming phosphoramidates, phosphonates, difluorophosphonates, oxophosphonates, and the like.